The Bridge Project focuses on bringing into the lives of patients new technical advances related to cancer detection and monitoring, targeted drug delivery, rapid mapping of drug resistance, and sustaining cancer-specific immune responses.
Bridge Project funding is currently being applied to make advances in the treatment of several cancer types that represent areas of great clinical need:
- Brain cancer
- Pediatric brain tumors
- Advanced breast cancer
- Advanced colon cancer
- Leukemia & Lymphoma
- Lung cancer
- Multiple myeloma
- Myelodysplastic syndromes
- Ovarian cancer
- Pancreatic cancer
- Advanced prostate cancer
The Bridge Project also welcomes proposals in the following areas:
- Cachexia in cancer
- Cancers with viral etiology (e.g., Merkel cell carcinoma)
- New technologies for tumor monitoring
- Mechanism-based molecular cancer prevention
BRIDGE PROJECT AWARDEES
Expansion Bridge Grant
These grants support previous awardees whose Bridge Project research is close to clinical trials/clinical application
- “Quantitative Tumor Oxygen Measurements in Cervical Cancer Patients,” a collaboration between Michael Cima of the Koch Institute, and Robert Cormack, Larissa Lee, and Ehud Schmidt of Brigham and Women's Hospital.
Traditional Bridge Project grants
These grants form the foundation of the Bridge Project, providing research funds to cross-institutional teams from MIT and DF/HCC who are focused on finding solutions to some of the most complex cancers.
- “Targeting Breast Cancer Cell Metabolism to Treat Brain Metastases,” a collaboration between Rakesh Jain of Massachusetts General Hospital and Matthew Vander Heiden of the Koch Institute.
- “Large Fingerprint Cancer Screening in Blood, “ a collaboration between J. Christopher Love of the Koch Institute and Mike Makrigiorgos and Heather Parsons of Dana-Farber Cancer Institute.
- “Targeting Aberrant Chromatin Structure in Cohesin-Mutated Myelodysplastic Syndrome,” a collaboration between Benjamin Ebert of Brigham and Women's Hospital and Richard Young of the Whitehead and Koch Institutes.
Footbridge grants are designed to enable the formation and growth of new teams, and support data collection and/or proof of concept work—and provide a potential path to full Bridge team funding.
- “Predicting Cancer Risk After Multi-Gene Panel Testing, Across All Cancer Types,” a collaboration between Regina Barzilay of MIT Computer Science & Artificial Intelligence Lab, Kevin Hughes of Massachusetts General Hospital, and Giovanni Parmigiani of Dana-Farber Cancer Institute and Harvard School of Public Health.
- “Quantitative microRNA Profiling in Cancer with Single Cell Resolution,” a collaboration between Patrick Doyle of the Koch Institute and Frank Slack of Beth Israel Deaconess Medical Center.
- “Novel Acute Myeloid Leukemia Differentiation Therapies Targeting Nucleosome Organization,” a collaboration between Andrew Lane of Dana-Farber Cancer Institute and Angela Koehler of the Koch Institute.
- “Developing PRMT5 Inhibitors with Improved Blood-Brain Barrier Penetration for Brain Tumor Treatment,” a collaboration between Jacqueline Lees of the Koch Institute and Jun Qi of Dana-Farber Cancer Institute.
2016 Bridge Project Pediatric Brain Tumors Projects
- “The DF/HCC-MIT Super Team Initiative for the Advancement of Diagnostics and Combination Therapeutics in Pediatric Brain Tumors,” a collaboration between Viktor Adalsteinsson, Broad Institute of MIT and Harvard, Rameen Beroukhim, Dana-Farber Cancer Institute, Paul Blainey, Broad Institute of MIT and Harvard, Paula Hammond, Koch Institute, Keith Ligon, Dana-Farber Cancer Institute, J. Christopher Love, Koch Institute, Karen Wright, Dana-Farber Cancer Institute, and Michael Yaffe, Koch Institute.
- “Targeting the Microenvironment of Pediatric High Grade Gliomas," a collaboration between Linda Griffith of the Koch Institute and MIT’s departments of Biological Engineering and Mechanical Engineering, Douglas Lauffenburger of the Koch Institute and MIT’s department of Biological Engineering, and Rosalind Segal, Dana-Farber Cancer Institute.
- “Engineering Synthetic Promoters and Viruses for Pediatric Glioma-specific Immunotherapy,” a collaboration between Samuel Rabkin of Massachusetts General Hospital, and Timothy Lu of the Koch Institute and MIT’s departments of Biological Engineering, Electrical Engineering and Computer Science.
- Inducing Non-Cell Autonomous Killing to Overcome Drug Resistance in Double-Hit Lymphoma
Collaborators: David Weinstock, MD (DFCI), Michael Hemann, PhD (Koch), and Ann LaCasce, MD (DFCI)
- A Phase I Clinical Trial Using an ALK Peptide Vaccine for ALK-Rearranged Non-Small Cell Lung Cancers
Collaborators: Mark Awad, MD, PhD (DFCI) and Roberto Chiarle, MD (BCH)
- Dendrimer-Replicon mRNA Nanoparticles to Deliver Neoantigen Vaccines in a Mouse Model of Pancreatic Cancer
Collaborators: Daniel Anderson, PhD (Koch) and Stephanie Dougan, PhD (DFCI)
- Designing Treatments for SMARCA4/BRG1-Mutant Lung Cancers
Collaborators: Carla Kim, PhD (BCH), Tyler Jacks, PhD (Koch), and Alice Shaw, MD, PhD (MGH)
- Targeting Transcriptional Amplification for the Treatment of Small Cell Lung Cancer Using a CDK7 Inhibitor
Collaborators: Nathanael Gray, PhD (DFCI), Kwok-Kin Wong (DFCI), and Richard Young (Whitehead/Koch)
- Systematic Discovery of Combination Immunotherapies for Melanoma
Collaborators: Chris Love, PhD (Koch), Alex Shalek, PhD (MIT), Kai Wucherpfennig, MD, PhD (DFCI), and Guo-Cheng Yuan, PhD (DFCI)
- Nanoparticle-Mediated RNAi Therapy in Bone Marrow to Prevent Multiple Myeloma Colonization
Collaborators: Ruben Carrasco, MD, PhD (DFCI), and Robert Langer (Koch)
- Predicting Drug Sensitivity in Lung Cancer by Single Mass Accumulation
Collaborators: Pasi Jänne, MD, PhD (DFCI) and Scott Manalis, PhD (Koch)
- Modulating the Heat-Shock Machinery to Limit Genetic Heterogeneity and the Evolution of Drug Resistance in Highly Malignant Cancers
Collaborators: Rameen Beroukhim, MD, PhD (DFCI), Susan Lindquist, PhD (Whitehead/Koch), and Sandro Santagata, MD, PhD (DFCI)
- Targeting Breast Cancer Cell Metabolism to Treat Brain Metastases
Collaborators: Rakesh Jain, PhD (MGH) and Matthew Vander Heiden, MD, PhD (Koch)
- Investigating MELK as a Novel Therapeutic Target in Triple-Negative Breast Cancer
Collaborators: Angelika Amon, PhD (Koch) and Jean Zhao, PhD (DFCI)
- A Novel in vivo Assay to Define Personalized Multi-drug Combination Therapy for Advanced Prostate Cancer
Collaborators: Steven Balk, MD, PhD (BIDMC), Glenn Bubley, MD (BIDMC), Akash Patnaik, MD, PhD (BIDMC), Xin Yuan (BIDMC), and Michael Yaffe, MD, PhD (Koch)
- Targeting Chemoresistant Disease in AML
Collaborators: Kimberly Stegmaier, MD (DFCI), Michael Hemann, PhD (Koch)
- Targeting Minimal Residual Disease in Acute Leukemias
Collaborators: David Weinstock, MD(DFCI), Scott Manalis, PhD (Koch)
- Development of an ALK Vaccine for Lung Cancer Treatment
Collaborators: Roberto Chiarle, MD (BCH), Darrell Irvine, PhD (Koch)
- Development of a Prototype Instrument Based on a Second-window Near-infrared Fluorescence Optical Imaging Modality for Detection and Monitoring of Deep-tissue Ovarian and Pancreatic Cancers
Collaborators: Michael Birrer, MD, PhD (MGH), Marcela del Carmen, MD (MGH), and Angela Belcher, PhD (Koch)
- Novel Agents for Targeting MCL-1 in Adult AML/ALL
Collaborators: Loren Walensky, MD, PhD (DFCI), Anthony Letai, MD, PhD (DFCI), and Amy Keating, PhD (MIT)
- Targeting Transcriptional Amplification for the Treatment of SCLC Using a CDK7 Inhibitor
Collaborators: Nathanael Gray, PhD (DFCI), Kwok-Kin Wong, MD, PhD (DFCI), and Richard Young, PhD (Whitehead/Koch)
- Detection of 'Invisible' Nevi in Redheads
Collaborators: Conor Evans, PhD (MGH), David Fisher, MD, PhD (MGH), and Peter So, PhD (MIT)
- Developing Novel Therapeutic Approaches in Small Cell Lung Carcinoma Using Genetically Engineered Mouse Models and Human Circulating Tumor Cells
Collaborators: Jeffrey Engelman, MD, PhD (MGH), Daniel Haber, MD, PhD (MGH), and Tyler Jacks, PhD (Koch)
- Osmotic Micro-Pump as Delivery System for Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer
Collaborators: Michael Birrer, MD, PhD (MGH), Marcela Del Carmen, MD (MGH), and Michael Cima, PhD (Koch)
- Targeting Mutant IDH1 in Malignant Gliomas
Collaborators:William Kaelin, MD (DFCI), Daniel Cahill, MD, PhD (MGH), and Matthew Vander Heiden, MD, PhD (Koch)
- A Pancreatobiliary Chemotherapy Eluting Stent for Pancreatic Ductal Adenocarcinomas
Collaborators: Jeffrey Clark, MD (MGH), Robert Langer, ScD (Koch) and Elazer Edelman, MD, PhD (MIT/Koch)
- Angiotensin Receptor Blockers (ARBs) as a Novel Approach to Improve Drug Delivery in the Treatment of Pancreatic Cancer
Collaborators: Rakesh Jain, PhD (MGH), Robert Langer, ScD (Koch)
- Novel Immunotherapies Against Pancreatic Cancer
Collaborators: Kai Wucherpfenni, MD, PhD (DFCI), J. Christopher Love, PhD (Koch), and Hidde Ploegh, PhD (Whitehead/Koch)
- Single-Cell Functional, Genomic and Transcriptomic Analysis in Glioblastoma
Collaborators: Keith Ligon, MD, PhD (DFCI), Matthew Meyerson, MD, PhD (DFCI/Broad), and J. Christopher Love, PhD(Koch)